Clinical Scorecard: Enrichment of Immature CD10low Neutrophils in Individuals Diagnosed with Multiple Sclerosis
At a Glance
Category
Detail
Condition
Multiple Sclerosis (MS)
Key Mechanisms
Immature CD10low neutrophils enriched in peripheral blood; neutrophils may contribute to early MS inflammation via antigen presentation, chemokine production, blood-brain barrier disruption, and NETs
Target Population
Individuals with recently active MS or clinically isolated syndrome (CIS)
Care Setting
Neurology clinics and research laboratories analyzing peripheral blood
Key Highlights
CD10low neutrophils with decreased CD16 and CD11b and absent CD184 expression are significantly enriched in blood of people with CIS/MS compared to controls
Proportions of CD10low neutrophils show a non-significant correlation with disability status (EDSS scores) in MS patients
Neutrophil subpopulations may serve as biomarkers and contribute to MS pathology, warranting further functional studies
Guideline-Based Recommendations
Diagnosis
Consider flow cytometry phenotyping of neutrophil subpopulations, including CD10 expression, in peripheral blood of newly diagnosed MS or CIS patients
Management
No current disease-modifying therapies targeting neutrophil subpopulations; corticosteroid use noted in some patients prior to sampling
Monitoring & Follow-up
Monitor neutrophil subpopulation proportions as potential biomarkers of disease activity in MS
Assess Expanded Disability Status Scale (EDSS) alongside neutrophil phenotyping for clinical correlation
Risks
Potential confounding effects of corticosteroid treatment on neutrophil phenotypes
Rapid processing of blood samples is essential to preserve neutrophil phenotype integrity
Patient & Prescribing Data
People with newly diagnosed MS or CIS, treatment-naïve or recently treated with corticosteroids
No specific neutrophil-targeted treatments currently; corticosteroids used in some cases but impact on neutrophil subpopulations requires further study
Clinical Best Practices
Collect and process peripheral blood samples within three hours to ensure accurate neutrophil phenotyping
Use multicolor flow cytometry panels optimized for neutrophil subpopulation analysis (e.g., OMIP-100)
Include clinical disability assessments (EDSS) when correlating neutrophil phenotypes with disease activity
Consider longitudinal studies to evaluate neutrophil subpopulation dynamics in MS progression
by Luke W. Garratt, Alice A. White, Craig Schofield, Jonatan Leffler, Prue H. Hart, Marzena J. Fabis-Pedrini, Allan G. Kermode, Anne Brüstle, Stephanie Trend
